Noninvasive Skin Cancer Test Detects Malignant Melanoma
|
By LabMedica International staff writers Posted on 31 Aug 2015 |

Image: The Laser Doppler Perfusion Monitor PeriFlux System (Photo courtesy of Perimed).
A special technique that uses a laser to detect the subtle differences in blood flow beneath the skin enabled scientists to tell the difference between malignant melanoma and noncancerous moles.
Skin malignant melanoma is a highly angiogenic cancer, necessitating early diagnosis for positive prognosis; however the current diagnostic standard of biopsy and histological examination inevitably leads to many unnecessary invasive excisions.
Scientists at Lancaster University (Bailrigg, UK) working with their colleagues at Pisa University (Italy), performed a cross-sectional study on 55 patients with atypical moles who agreed to have their skin monitored by a laser Doppler system. A clinically atypical nevus was defined as a skin melanocytic lesion with one or more of the following clinical features: asymmetry, border irregularity, color variability and a diameter greater than six mm. Healthy subjects with a clinically benign nevus and patients affected by non-active psoriasis were also recruited as control subjects. Following blood perfusion monitoring, subjects diagnosed with an atypical nevus underwent excision of the lesion, which was then histologically examined.
Blood perfusion monitoring was carried out in the mornings using a Periflux PF4 single point laser Doppler flowmetry apparatus (LDF), (Perimed; Järfälla, Sweden) equipped with an unheated probe. The laser characteristics were: 780 nm wavelength, 10 Hz–19 kHz bandwidth, 0.1 second time constant, 32 Hz sampling frequency. Probe calibration was performed before each session, using a specialized device. The laser Doppler was used to record the complex interactions taking place in the minute blood vessels beneath their suspicious mole for around 30 minutes. The fluctuations in recorded signals were then analyzed using methods developed by physicists at Lancaster University.
On histological examination, the 54 clinically atypical nevi included in the final data resulted in skin malignant melanoma in 10 cases, benign atypical nevi in 33 cases and benign typical nevi in 11 cases. The skin malignant melanoma (SMM) group showed significantly higher average blood flow values at lesion centers and margins compared to both the histologically atypical and the benign typical nevi. The laser Doppler signal correctly identified 100% of the patients with malignant skin.
Aneta Stefanovska, PhD, a professor and a senior author of the study, said, “We used our knowledge of blood flow dynamics to pick up on markers which were consistently different in the blood vessels supplying malignant moles and those beneath normal skin. Combining the new dynamical biomarkers we created a test which, based on the number of subjects tested to date, has 100% sensitivity and 90.9% specificity, which means that melanoma is identified in all cases where it is present, and ruled out in 90.9% of cases where it is not.” The study was published on August 11, 2015, in Nature Scientific Reports.
Related Links:
Lancaster University
Pisa University
Perimed
Skin malignant melanoma is a highly angiogenic cancer, necessitating early diagnosis for positive prognosis; however the current diagnostic standard of biopsy and histological examination inevitably leads to many unnecessary invasive excisions.
Scientists at Lancaster University (Bailrigg, UK) working with their colleagues at Pisa University (Italy), performed a cross-sectional study on 55 patients with atypical moles who agreed to have their skin monitored by a laser Doppler system. A clinically atypical nevus was defined as a skin melanocytic lesion with one or more of the following clinical features: asymmetry, border irregularity, color variability and a diameter greater than six mm. Healthy subjects with a clinically benign nevus and patients affected by non-active psoriasis were also recruited as control subjects. Following blood perfusion monitoring, subjects diagnosed with an atypical nevus underwent excision of the lesion, which was then histologically examined.
Blood perfusion monitoring was carried out in the mornings using a Periflux PF4 single point laser Doppler flowmetry apparatus (LDF), (Perimed; Järfälla, Sweden) equipped with an unheated probe. The laser characteristics were: 780 nm wavelength, 10 Hz–19 kHz bandwidth, 0.1 second time constant, 32 Hz sampling frequency. Probe calibration was performed before each session, using a specialized device. The laser Doppler was used to record the complex interactions taking place in the minute blood vessels beneath their suspicious mole for around 30 minutes. The fluctuations in recorded signals were then analyzed using methods developed by physicists at Lancaster University.
On histological examination, the 54 clinically atypical nevi included in the final data resulted in skin malignant melanoma in 10 cases, benign atypical nevi in 33 cases and benign typical nevi in 11 cases. The skin malignant melanoma (SMM) group showed significantly higher average blood flow values at lesion centers and margins compared to both the histologically atypical and the benign typical nevi. The laser Doppler signal correctly identified 100% of the patients with malignant skin.
Aneta Stefanovska, PhD, a professor and a senior author of the study, said, “We used our knowledge of blood flow dynamics to pick up on markers which were consistently different in the blood vessels supplying malignant moles and those beneath normal skin. Combining the new dynamical biomarkers we created a test which, based on the number of subjects tested to date, has 100% sensitivity and 90.9% specificity, which means that melanoma is identified in all cases where it is present, and ruled out in 90.9% of cases where it is not.” The study was published on August 11, 2015, in Nature Scientific Reports.
Related Links:
Lancaster University
Pisa University
Perimed
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







